Raredr

A New Era in Hearing Loss Protection For Cancer Patients

David Freyer, DO
Published Online: May 4, 2017


David Freyer, DO, of the Children's Hospital of Los Angeles praises the clinical trial he was involved with showing that the administration of sodium thiosulfate (STS) in pediatric cancer patients receiving cisplatin reduced the number of patients developing hearing loss. 
 
This landmark trial was the first of its kind and Dr Freyer is looking forward to future studies in this field to provide options for patients, especially pediatric patients, undergoing platinum-based cancer therapy. 

Reference 

Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:63-74. doi: 10.1016/S1470-2045(16)30625-8


Latest Articles
Positive initial results from a Phase 1A clinical trial evaluating setmelanotide (RM-492) for the treatment of rare genetic disorders of obesity were reported.
He’s a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
Dr Gavin Rumbaugh, PhD of Scripps Florida Research Institute was awarded an NIMH-funded grant for the therapeutic development of Syngap1.
Cooper sits down with RDR to talk about A4250, why it’s so important to children with PFIC, and just how Albireo prioritizes treatment for rare diseases.
$vacMongoViewPlus$ $vAR$